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Aim: The main purpose of this work was to develop a pharmacokinetic model for the
bone pain palliation agent Samarium-153 ethylenediamine tetramethylene phosphonate
([153Sm]-EDTMP) in normal rats to analyze the behavior of the complex.
Background: The use of compartmental analysis allows a mathematical separation of tissues
and  organs to determine the concentration of activity in each fraction of interest. Biodis-
tribution studies are expensive and difﬁcult to carry out in humans, but such data can be
obtained easily in rodents.
Materials and methods: We  have developed a physiologically based pharmacokinetic model
for  scaling up activity concentration in each organ versus time. The mathematical model
uses physiological parameters including organ volumes, blood ﬂow rates, and vascular per-
mabilities; the compartments (organs) are connected anatomically. This allows the use of
scale-up techniques to predict new complex distribution in humans in each organ.
Results: The concentration of the radiopharmaceutical in various organs was measured at
different times. The temporal behavior of biodistribution of 153Sm-EDTMP was modeled and
drawn as a function of time.Conclusions: The variation of pharmaceutical concentration in all organs is described with
summation of 6–10 exponential terms and it approximates our experimental data with
precision better than 2%.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All∗ Corresponding author. Tel.: +98 2122803280.
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.  Background
ccording to the principles of humane experimental tech-
ique, the use of other researchers’ data has been one of the
ainly recommended actions allowing the 3Rs concepts to
educe the number of experimental procedures involving ani-
al  and improve results.1 In the same way, compartmental
nalyses support the radiopharmaceuticals design permitting
 mathematical separation of tissues and organs to determi-
ate the concentration of activity in each fraction of interest
nd pointing toward inconsistency in biodistribution and
osimetry studies. Additionally, by compartmental analysis
t is possible to consider different chemical species and to
redict metabolites.2
Mathematical models that describe the kinetic processes
f a particular agent may be used to predict its behavior
n regions where direct measurements are not possible but
here sufﬁcient independent knowledge about the physiol-
gy of the region is available to specify its interrelationship
ith the regions or tissues in which uptake and retention can
e measured directly. These models can account for the pres-
nce of metabolic products.3–6 Compartmental modeling is
he most commonly used method for describing the uptake
nd clearance of radioactive tracers in tissue.7–9 These models
pecify that all molecules of tracer delivered to the system (i.e.,
njected) will at any given time exist in one of many  compart-
ents. Each compartment deﬁnes one possible state of the
racer, speciﬁcally its physical location (for example, intravas-
ular space, extracellular space, intracellular space, synapse)
nd its chemical state (i.e., its current metabolic form or its
inding state to different tissue elements, such as plasma pro-
eins, receptors). Often, a single compartment represents a
umber of these states lumped together. Compartments are
ypically numbered for mathematical notation.10
The compartmental model also describes the possible
ransformations that can occur to the tracer, allowing it to
ove between compartments. The model deﬁnes the fraction
r proportion of tracer molecules that will move to a differ-
nt compartment within a speciﬁed time. This fractional rate
f change of the tracer concentration in one compartment is
alled a rate constant and has units of inverse time.10
The physiological interpretation of the source and destina-
ion compartments deﬁnes the meaning of the rate constants
or movement  of tracer between them. For a freely diffusible
nert tracer, the rate constant of transfer from arterial blood to
he tissue compartment will deﬁne local blood ﬂow. By deter-
ining these rate constants (or some algebraic combination of
hem), quantitative estimates or indices of local physiological
arameters can be obtained. The underlying goal of all mod-
ling methods is the estimation of one or more  of these rate
onstants from tissue radioactivity measurements.2,10
In this study, the compartmental analyses were used
o generate a time-dependence model of biodistribution of
153Sm]-EDTMP, an agent for bone palliation radiotherapy.
hemotherapy or hormonal therapy may be used for both
oft tissue and bone metastases and can be effective until
he disease becomes refractory to these agents. External
eam radiotherapy provides effective pain control with short
ourses of high dose per fraction and a low toxicity, if theFig. 1 – Chemical structure of [153Sm]-EDTMP.
metastatic disease is not extensive; however, the toxicity
rapidly increases with wide radiation ﬁelds.11
Systemic therapy with radionuclides linked to bone seeking
agents is a treatment option for patients with dissemi-
nated skeletal metastases, owing to its efﬁcacy, low cost and
low toxicity.12 Radionuclides suitable for systemic metabolic
radiotherapy of bone pain include Phosphorous-32 (P-32),
Strontium-89 (Sr-89), Rhenium-186 (Re-186) chelated with
hydroxyethylidene diphosphonate (HEDP) and Samariumm-
153 (Sm-153) chelated with ethylenediamine tetramethylene
phosphonate (EDTMP).13–16
Considerable bone marrow suppression due to the pres-
ence of higher energy  particles is a major constraint toward
a widespread use of P-32 (mean  ˇ = 695 keV, t1/2 = 14.3 days)
and Sr-89 (mean  ˇ = 583 keV, t1/2 = 50.5 days). Apart from that,
the absence of imageable  photons and long half life (espe-
cially in case of Sr-89) are often cited as drawbacks. Beta
emitters with short half-lives, like Re-186 (mean  ˇ = 362 keV,
 = 137 keV, t1/2 = 3.7 days) and Sm-153 (mean  ˇ = 233 keV,
 = 103 keV, t1/2 = 1.9 days), deliver their radiation dose at higher
dose rates, which may be therapeutically more  effective than
equivalent doses given at lower dose rates. The short range of
beta emission of these radionuclides may be of advantage in
limiting red marrow irradiation.17 Beside beta ray, 153Sm emits
gamma radiation and conversion electrons with 103 keV and
55 keV energies, respectively. Gamma  ray at this energy range
makes nuclear imaging feasible, while the process of radio-
therapy is carried out. Finally, 153Sm decays to stable nuclide
153Eu.18,19 153Sm-ethylenediamine tetramethylene phospho-
nic acid ([153Sm]-EDTMP) (Fig. 1) localizes in the skeleton
by chemo-absorption of the tetraphosphonate by hydroxy-
apatite and by the formation of Samarium oxide involving
oxygen on the hydroxyapatite molecule. Early phase I/II stud-
ies were published more  than ten years ago and since then,
this agent has been clinically used worldwide for pain palli-
ation in symptomatic bone metastases from several cancers,
mainly prostate and breast.20–22
Mathematical biodistribution models are an alternative
approach to the direct calculation of cumulated activity in the
ﬁeld of radiopharmaceuticals dosimetry. Often, it is imprac-
tical to measure the time–activity curves of all the source
regions. When the physiological interactions of these regions
with the blood or with other directly measurable tissues are
known, the time–activity curves of unmeasured tissues can be
inferred by these models. Biodistribution modeling can also
be used to separate the activities in the regions that overlap
d rad216  reports of practical oncology an
on imaging studies, such as the renal cortex and renal pelvis
or the liver and right colon.6 In the future, the biodistribution
modeling will play an important role in molecular imaging and
in vivo dosimetry.
2.  Aim
Samarium, being a lanthanide metal, concentrates in bone,
especially tissues with high osteoblastic activity. This gives
the beneﬁt of its absorption in metastatic tissues in bone
cancer. As a rule of thumb, concentration of Samarium in
metastatic bone tissues is ﬁve times higher than in normal
tissue.23 153Sm-ethylenediamine tetramethylene phosphonic
acid ([153Sm]-EDTMP) is a major therapeutic agent which is
widely used in the world.2 In this work, time dependant bio-
distribution model of [153Sm]-EDTMP was procured by using
compartmental analysis with respect to anatomic data from
ICRP Report 89.
3.  Materials  and  methods
Data used in the present work were: original percentage of
internal dose per gram data from Goeckeler et al.24 [153Sm]-
EDTMP long-term biodistribution studies in 160–220 g male
Sprague–Dawley rats.
3.1. 153Sm-EDTMP  complex  preparation
Stable Samarium, 152Sm,  is a lanthanide with high absorp-
tion cross section for thermal neutrons (204 barns) leading to
production of 153Sm.2 The radionuclide was prepared by neu-
tron irradiation in the University of Missouri Research Reactor
using a thermal ﬂux of 8.5 × 1013 n/cm2 s and a resonance ﬂux
of 1.7 × 1012 n/cm2 s. The radioisotope was dissolved in 1–4 N
HCl and brought to a stock concentration of approximately
1.2 × 10−3 M with deionized water.24
To form [153Sm]-EDTMP complex, 50 mg/ml  of EDTMP that
was prepared by Dow chemical company was used. The
amount of ligand needed to achieve a quantitative complex
formation25 was ﬁrst dissolved in deionized water followed by
the addition of concentrated base. The 153Sm stock and carrier
solutions were added so that the ﬁnal samarium concentra-
tion was ∼3.0 × 10−4 M with a speciﬁc activity of 185 MBq/ml.
The pH was adjusted to >10 and the solution heated to 60 ◦C
for ∼30 min  to facilitate complexation. After heating, the pH
was adjusted to 7.0 with 4–5 M HCl.24
Complex yield was determined by separating the com-
plexed metal and uncomplexed 153Sm species on a 0.5-ml
C25 Sephadex cationic exchange column. The ionic samarium
(Sm+3) and insoluble Sm(OH)3 were retained on the column
while the anionic complex was eluted with two 9-ml volumes
of isotonic saline.24
The elution and columns were counted using the 103-keV
gamma photon of 153Sm and the complex yield (% complex)
24was obtained from the formula :
Complex (%) = 100 ×
(
1 − column count
total count
)
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Samples were counted in a NaI(Tl) well counter and cor-
rected for background.
3.2.  Biodistribution  of  [153Sm]-EDTMP  in  rats
Samarium-153 EDTMP was prepared as previously described
using a ligand concentration of 8.0 × 10−2 M and a samarium
concentration of 3.0 × 10−4 M,  the complex yield was >99%.
Fifty microliters of the complex were injected into the tail
veins of male Sprague–Dawley rats. Each rat was housed in a
metabolic cage equipped to collect urine. They were killed in
groups of ﬁve by cervical dislocation at 2 h, 5 h, 24 h, 48 h, and
72 h post-injection. A 1-ml sample of blood was drawn from
the heart and weighed immediately after killing. The whole
animal was then weighed and subsequently dissected with
special care being taken to separate the blood and urine on
the kill papers, the tissue washings and the urine collected
from the cages. All tissues were washed with isotonic saline,
blotted, weighed, and counted. Animals maintained for 24 h or
more  were provided with ad lib. standard rat chow and water.
Counting was performed for all tissues in the longer time
period groups which were counted in a NaI(Tl) well detector
and compared with diluted standards.
3.3.  Biodistribution  modeling  of  [153Sm]-EDTMP
The ﬁrst approach of the modeling studies included the knowl-
edge of chemical kinetics and mimetism of the Samarium and
possible targets of the diagnosis/therapy to choose possible
models to apply over the sampling standard methods used in
experimental works.
Biodistribution modeling consisted of two steps. At the ﬁrst
stage, a model with only one physical compartment (whole
body) and one chemical compartment ([153Sm]-EDTMP) were
generated with the compartmental analysis. The values used
in this work were residence time from three different kinds
of study with free 153Sm:  whole body, average excretion and
maximum excretion as a chemical compartment. Activity con-
centration values as a time function in measurements of total
whole body and activity measurement in samples of blood
with projection to total circulating blood volume with [153Sm]-
EDTMP. Considering the two sources of data in the same
modeling a better consistence was obtained.
The second step was a statistic treatment of biodis-
tribution and dosimetry in rats considering three chemical
fractions of the designed radiopharmaceutical: [153Sm]-
EDTMP, free 153Sm,  and total radiopharmaceutical (free
153Sm + ([153Sm]-EDTMP)) (Fig. 2). Using a mamillar models
with six compartments and Human anatomic data from ICRP
Report 89, these studies were also performed in rats. The
selected parameters were very critical, considering the blood
ﬂux in each body region and tissue.
4.  ResultsWith the concentration of ligand used in preparation of
[153Sm]-EDTMP, complex yield was >99%. Before the complex
was injected into the animals, its pH was lowered to ∼7 with no
detectable complex dissociation. The activity concentration in
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Fig. 2 – Selected compartmental analysis models scheme. (A) One physical compartment (whole body) and one chemical
compartment (153Sm-EDTMP). (B) One physical compartment (whole body) and two chemical compartments (153Sm-EDTMP
a
e
ﬁ
T
i
l
o
bnd 153Sm-free). (C) Six compartment model of a rat.
ach organ was measured with the use of detectors at speci-
ed time after injection. The results show variation with time.
able 1 includes the uptake (%ID/g) data of the [153Sm]-EDTMP
n various organs of rats.
153[ Sm]-EDTMP demonstrated high skeletal uptake with
ow blood concentration at 2 h post-injection. Localization
f [153Sm]-EDTMP in nonosseous tissues was also low. The
one to blood activity concentration ratio was about 300at 24 h and 72 h post-injection. The bone to muscle ratios
were more  than 16 at 24 h and more  than 23 at 72 h
post-injection.
The compartmental model was used to produce a
mathematical description of these variations. The fol-
lowing equations were obtained for each organ. In
each case, t = 0 corresponds to the time of injection
(Fig. 3).
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Table 1 – Biodistribution of [153Sm]-EDTMP in rats as a function of time after injection.
Organs Injected dose per gram (ID/g% ± SD) [153Sm]-EDTMP
2 h 5 h 24 h 48 h 72 h
Blood 0.032 ± 0.016 0.008 ± 0.019 0.007 ± 0.002 0.006 ± 0.001 0.006 ± 0.001
Heart 0.010 ± 0.009 0.006 ± 0.003 0.006 ± 0.002 0.008 ± 0.004 0.007 ± 0.003
Lung 0.021 ± 0.007 0.016 ± 0.005 0.007 ± 0.002 0.008 ± 0.002 0.008 ± 0.001
Liver 0.252 ± 0.038 0.370 ± 0.080 0.349 ± 0.021 0.458 ± 0.079 0.492 ± 0.097
Spleen 0.006 ± 0.004 0.007 ± 0.005 0.007 ± 0.002 0.009 ± 0.003 0.007 ± 0.004
Stomach 0.241 ± 0.015 0.059 ± 0.003 0.024 ± 0.005 0.081 ± 0.008 0.058 ± 0.002
Intestine 0.095 ± 0.021 0.270 ± 0.017 0.055 ± 0.001 0.081 ± 0.007 0.058 ± 0.002
Kidneys 0.254 ± 0.035 0.364 ± 0.055 0.250 ± 0.087 0.286 ± 0.028 0.216 ± 0.036
Muscle 0.223 ± 0.037 0.064 ± 0.004 0.125 ± 0.008 0.120 ± 0.020 0.097 ± 0.004
Bone 2.308 ± 0.162 2.341 ± 0.173 2.082 ± 0.116 2.381 ± 0.151 2.276 ± 0.160Fig. 3 – Temporal behavior of biodistribution of 153Sm-EDTMP in various organs of wild-type rat.
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1) Blood
f1 = (5.175E–3)e−(9.9E–3)t+(9.89E–3)e−0.077t+(3.956E–5)e−0.07t
+ (2.254E–4)e−0.001t + (2.1275E–2)e−0.38t
− (5.964E–6)e−5.14t–(3.266E–8)e−0.24t
2) Heart
f2 = (7.70133E–2)e−1.64t + (4.14687E–4)e−0.14t
+ (4.21848E–4)e0.006t + (3.22896E–3)e0.019t
+ (3.6456E–3)e−0.091t − (3.7107E–5)e0.0706t
− (1.03509E–1)e−3.04t
3) Bone
f3 = 1.956e(9.9E–3)t + (29.6E–1)e−0.047t + (1.26E–2)e0.0911t
− (2.34E–1)e−9.14t − (6.00E–4)e−1.13t − (3.24E–1)e−0.18t
− (2.352E–2)e−0.00612t − 3.34242e−1.08t
4) Intestine
f4 = 14.54703e−1.64t + (7.230306E–1)e−0.45t
+ (3.538337E–2)e−0.14t + (3.111048E–2)e0.006t
+ (2.30448E–1) e0.019t + (4.60896E–3)e−0.191t
− (7.63359E–2)e−5.04t − 1.9204e−0.777t
5) Kidney
f5 = (2.608E–1)e(9.9E–3)t + (1.28E–1)e−0.047t + (1.84E–3)e0.0911t
− (3.12E–2)e−9.14t − (6.4E–5)e−1.13t − (6.4E–3)e−0.18t
− (3.136E–2)e−0.00612t − 1.885656e−1.38t
6) Liver
f6 = (2.7873E–2)e(9.9E–4)t + (1.368E–1)e−0.037t
+ (1.9665E–3)e0.0911t − (3.3516E–4)e−0.00512t
− (3.1635E–2)e−9.14t − (4.8564E–2)e−1.13t
− (1.6074E–2)e−0.06t − 1.33129485e−1.18t
7) Lung
−(9.9E–6)t −0.26tf7 = (8.00E–4)e + (3.8736E–2)e
+ (1.376E–4)e−0.062t + (2.4784E–3)e−0.001t
− (1.08E–2)e−0.077t + (1.12E–3)e0.0523ttherapy 1 9 ( 2 0 1 4 ) 214–220 219
− (2.3941546E–2)e−0.42t − (3.1412E–4)e−0.017t
− (2.3141412E–2)e−1.18t − (2.58E–5)e0.0999t
(8) Spleen
f8 = (6.846E–3)e−(9.9E–3)t+(3.36E–3)e−0.047t−(4.83E–5)e0.0911t
− (5.019E–3)e−9.14t − (2.0328E–3)e−1.13t−(1.68E–5)e−0.18t
− (8.232E–4)e−0.00612t − (8.309847E–2)e−1.38t
(9) Stomach
f9 = (3.686627E–3)e−5.04t + (3.0899E–1)e−1.64t
+ (3.9061E–3)e−0.14t + (3.4344E–3)e0.006t
+ (2.544E–2)e0.019t + (4.558E–2)e−0.091t
The deviation of [153Sm]-EDTMP concentration in all organs
and tissues is described with summation of seven to nine
exponential terms. Comparison with animal data showed that
our experimental data with precision better than 2%. It should
be noted that the concentration of activity had been in a good
statistics range of measurement.
5.  Conclusion
In this work, time dependant biodistribution model of [153Sm]-
EDTMP was procured by using compartmental analysis with
respect to anatomic data from ICRP Report 89. Biodistribution
studies of [153Sm]-EDTMP were carried out in wild-type rats
comparing the critical organ uptakes. Comparative studies for
the labeled compound were conducted up to 48 h, demonstrat-
ing a more  rapid wash out of activity for the labeled compound.
The radioactivity in the case of the labeled compound is sig-
niﬁcantly removed from the blood and bone.
As a result of modeling, the variation of pharmaceutical
concentration in all organs is described with summation of
6–10 exponential terms and it approximates our experimental
data with precision better than 2%.
There are many  future studies that can be done in order to
add to these models. Eventual goals include incorporating the
action of beta-emitting nuclides in order to observe the toxic-
ity and its effect on the killing of cells. A stochastic approach
can be taken to model beta emission, because the distance a
particle is emitted varies randomly over time; this theoretical,
improved model can be implemented into a full simulation
involving dosimetry calculations.
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